Notably, the drugs Cotadutide, Survodutide, Efinopegdutide, Pemvidutide, and Bamadutide have been developed as GLP1-R/glucagon receptor agonists and can increase energy expenditure and decrease food intake and hepatic lipogenesis, counteracting the detrimental effects of obesity [112]. Here, GLP1R is linked to Obesity.